Clinical outcomes in stage III non-small cell lung cancer patients treated with durvalumab after sequential or concurrent platinum-based chemoradiotherapy – single institute experience
Chemoradiotherapy (ChT-RT) followed by 12-month durvalumab is the new standard treatment for unresectable stage III non-small cell lung cancer. Survival data for patients from everyday routine clinical practice is scarce, as well as potential impact on treatment efficacy of sequential or concomitant...
Guardado en:
Autores principales: | , , , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Sciendo
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ae2e857754654969af9f34a239d8657f |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:ae2e857754654969af9f34a239d8657f |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:ae2e857754654969af9f34a239d8657f2021-12-05T14:11:10ZClinical outcomes in stage III non-small cell lung cancer patients treated with durvalumab after sequential or concurrent platinum-based chemoradiotherapy – single institute experience1581-320710.2478/raon-2021-0044https://doaj.org/article/ae2e857754654969af9f34a239d8657f2021-11-01T00:00:00Zhttps://doi.org/10.2478/raon-2021-0044https://doaj.org/toc/1581-3207Chemoradiotherapy (ChT-RT) followed by 12-month durvalumab is the new standard treatment for unresectable stage III non-small cell lung cancer. Survival data for patients from everyday routine clinical practice is scarce, as well as potential impact on treatment efficacy of sequential or concomitant chemotherapy and the usage of gemcitabine.Vrankar MartinaStanic KarmenJelercic StasaCiric EvaVodusek Ana LinaBut-Hadzic JasnaSciendoarticlenon-small cell lung cancerstage iiichemoradiotherapydurvalumabMedical physics. Medical radiology. Nuclear medicineR895-920ENRadiology and Oncology, Vol 55, Iss 4, Pp 482-490 (2021) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
non-small cell lung cancer stage iii chemoradiotherapy durvalumab Medical physics. Medical radiology. Nuclear medicine R895-920 |
spellingShingle |
non-small cell lung cancer stage iii chemoradiotherapy durvalumab Medical physics. Medical radiology. Nuclear medicine R895-920 Vrankar Martina Stanic Karmen Jelercic Stasa Ciric Eva Vodusek Ana Lina But-Hadzic Jasna Clinical outcomes in stage III non-small cell lung cancer patients treated with durvalumab after sequential or concurrent platinum-based chemoradiotherapy – single institute experience |
description |
Chemoradiotherapy (ChT-RT) followed by 12-month durvalumab is the new standard treatment for unresectable stage III non-small cell lung cancer. Survival data for patients from everyday routine clinical practice is scarce, as well as potential impact on treatment efficacy of sequential or concomitant chemotherapy and the usage of gemcitabine. |
format |
article |
author |
Vrankar Martina Stanic Karmen Jelercic Stasa Ciric Eva Vodusek Ana Lina But-Hadzic Jasna |
author_facet |
Vrankar Martina Stanic Karmen Jelercic Stasa Ciric Eva Vodusek Ana Lina But-Hadzic Jasna |
author_sort |
Vrankar Martina |
title |
Clinical outcomes in stage III non-small cell lung cancer patients treated with durvalumab after sequential or concurrent platinum-based chemoradiotherapy – single institute experience |
title_short |
Clinical outcomes in stage III non-small cell lung cancer patients treated with durvalumab after sequential or concurrent platinum-based chemoradiotherapy – single institute experience |
title_full |
Clinical outcomes in stage III non-small cell lung cancer patients treated with durvalumab after sequential or concurrent platinum-based chemoradiotherapy – single institute experience |
title_fullStr |
Clinical outcomes in stage III non-small cell lung cancer patients treated with durvalumab after sequential or concurrent platinum-based chemoradiotherapy – single institute experience |
title_full_unstemmed |
Clinical outcomes in stage III non-small cell lung cancer patients treated with durvalumab after sequential or concurrent platinum-based chemoradiotherapy – single institute experience |
title_sort |
clinical outcomes in stage iii non-small cell lung cancer patients treated with durvalumab after sequential or concurrent platinum-based chemoradiotherapy – single institute experience |
publisher |
Sciendo |
publishDate |
2021 |
url |
https://doaj.org/article/ae2e857754654969af9f34a239d8657f |
work_keys_str_mv |
AT vrankarmartina clinicaloutcomesinstageiiinonsmallcelllungcancerpatientstreatedwithdurvalumabaftersequentialorconcurrentplatinumbasedchemoradiotherapysingleinstituteexperience AT stanickarmen clinicaloutcomesinstageiiinonsmallcelllungcancerpatientstreatedwithdurvalumabaftersequentialorconcurrentplatinumbasedchemoradiotherapysingleinstituteexperience AT jelercicstasa clinicaloutcomesinstageiiinonsmallcelllungcancerpatientstreatedwithdurvalumabaftersequentialorconcurrentplatinumbasedchemoradiotherapysingleinstituteexperience AT ciriceva clinicaloutcomesinstageiiinonsmallcelllungcancerpatientstreatedwithdurvalumabaftersequentialorconcurrentplatinumbasedchemoradiotherapysingleinstituteexperience AT vodusekanalina clinicaloutcomesinstageiiinonsmallcelllungcancerpatientstreatedwithdurvalumabaftersequentialorconcurrentplatinumbasedchemoradiotherapysingleinstituteexperience AT buthadzicjasna clinicaloutcomesinstageiiinonsmallcelllungcancerpatientstreatedwithdurvalumabaftersequentialorconcurrentplatinumbasedchemoradiotherapysingleinstituteexperience |
_version_ |
1718371315690242048 |